

GAU 1644



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 27 2001

TECH CENTER 1600/2900

Applicants:

Marc Feldmann and Ravinder N. Maini

Application No.: 09/754,004

Group Art Unit: 1644

Filed: January 3, 2001

Examiner: Not Assigned

Title: TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT
OF TNF-MEDIATED DISEASE

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>4/23/01</u>	<u>Sandra Jammal</u>
Date	Signature
<u>Sandra Jammal</u>	
Typed or printed name of person signing certificate	

REVOCATION OF POWERS OF ATTORNEY
AND APPOINTMENT OF NEW ATTORNEYS AND/OR AGENTS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The Kennedy Institute of Rheumatology, a Corporation duly organized under the laws of the United Kingdom, is the assignee of the entire right, title and interest in the above-identified application. The Kennedy Institute of Rheumatology hereby appoints:

John P. White, Esq.
Registration No.: 28,678
Cooper & Dunham
1185 Avenue of the Americas
New York, New York 10036

to prosecute the above-identified application and any divisions or continuations thereof and to conduct all business in the United States Patent and Trademark Office. All previously granted Powers of Attorney are hereby revoked.

Certification under 37 C.F.R. §3.73(b) is submitted herewith.

All correspondence should be sent to John P. White, Esq., Cooper & Dunham, 1185 Avenue of the Americas, New York, New York 10036. Please direct all telephone calls to John P. White, Esq. at (212) 278-0421, and all facsimile communications to (212) 391-0525.

Respectfully submitted,

The Kennedy Institute of Rheumatology

By Ravinder N. Maini

Ravinder N. Maini

^{Honorary}
Title: Director, and Trustee
The Kennedy Institute of Rheumatology

Date 18/4/2001

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)**RECEIVED**

APR 27 2001

Applicant: Marc Feldmann and Ravinder N. MainiApplication No.: 09/754,004 Filed: January 3, 2001

TECH CENTER 1600/2900

For: TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASEThe Kennedy Institute of Rheumatology, aCorporation,

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

certifies that it is

- A. ☒ the assignee of the entire right, title and interest in the patent application identified above.
- B. ☐ an assignee together with [] of the entire right, title and interest in the patent application identified above. A separate Certificate under 37 CFR § 3.73(b) is attached.

The right, title and interest of the above-named assignee in the patent application identified above is established by virtue of:

- A. ☒ An assignment from the inventors of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 8168, Frame 0822-0824, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are attached.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 18/4/2001Name: Ravinder N. MainiTitle: Director, The Kennedy Institute of RheumatologySignature: Rmaini